Citeline, a Norstella company

Jamp Pharma has secured Health Canada approval for Upgolyv, a golimumab biosimilar to Simponi, expanding its Canadian immunology portfolio, strengthening its BioJamp division and advancing its strategy in high-growth specialty medicines.

Data from Xenon at the American Academy of Neurology meeting confirm azetukalner's Phase III efficacy in epilepsy ahead of a Q3 NDA filing.

Data at the American Academy of Neurology support argenx’s bid to expand Vyvgart's reach in myasthenia gravis.

The EU’s Digital Omnibus legislation delegates some AI medtech regulation to MDR – a role it is not necessarily built for.

Join our Japan-based team for an audio roundup of key developments in the country's biopharma industry over the first few months of this year.

Join our Japan-based team for an audio roundup of key developments in the country's biopharma industry over the first few months of this year.

The Iran war has turned the region into a powder keg and pharma in India is tackling systemic supply chain shocks with some solvent/chemical suppliers declaring force majeure, and also related contract stress. Could the compounding pressures spillover to other markets?

A prolonged US blockade of Iranian ports might cause a supply chain impact so far restricted to Asia to spread wider in the mid-term. Experts believe generic drug shortages could result from portfolio restructuring, though innovator drugs remain largely insulated for now.